ClinicalTrials.gg
CompletedNCT01797445Updated Mar 2, 2020Results posted

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 117 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.

Enrollment
2nd of 11
872 · median 252
Started
2013
with 6 others
Phase 3
7 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
11 of 11
Gilead Sciences

Among the 11 studies testing elvitegravir in HIV Infections, this one is the 2nd largest by enrollment, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 5th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About elvitegravir

elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing elvitegravir in HIV Infections as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.

03

Conditions studied

  • HIV
  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Treatment Naive
  • HIV 1 Infected
  • Women
  • Female
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Plasma -1 RNA levels ≥ 1,000 copies/mL at screening
  • No prior use of any approved or antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PREP), or post-exposure prophylaxis (PEP) up to 6 months prior to screening
  • Screening genotype report must show sensitivity to elvitegravir, emtricitabine, tenofovir DF
  • Normal (ECG)
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • Hepatic transaminases ( and ALT) ≤ 5 × (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Males and females of must agree to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug
  • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the range based on the Central Laboratory reference range
  • Age ≥ 18 years

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening
  • surface antigen (HBsAg) positive
  • antibody positive
  • Individuals experiencing decompensated cirrhosis
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial (including observational trials) without prior approval
  • Receiving ongoing therapy with drugs not to be used with elvitegravir, cobicistat, emtricitabine, tenofovir DF, and TAF or participants with any known allergies to the of E/C/F/TDF or E/C/F/TAF

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
872 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF (Double-Blind)

    E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded.

    Drug: E/C/F/TAF · Drug: E/C/F/TDF Placebo

  • Active comparator
    E/C/F/TDF (Double-Blind)

    E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded.

    Drug: E/C/F/TDF · Drug: E/C/F/TAF Placebo

  • Experimental
    Open-Label E/C/F/TAF

    After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.

    Drug: E/C/F/TAF

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: Genvoya®

  • DrugE/C/F/TDF

    150/150/200/300 mg FDC tablet administered orally once daily

    Also known as: Stribild®

  • DrugE/C/F/TDF Placebo

    Tablet administered orally once daily

  • DrugE/C/F/TAF Placebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  2. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Weeks 48 and 96

  3. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  4. Change From Baseline in CD4+ Cell Count at Week 96

    Time frame: Baseline; Week 96

  5. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

    Time frame: Baseline; Week 48

  6. Percent Change From Baseline in Hip BMD at Week 96

    Hip BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  7. Percent Change From Baseline in Spine BMD at Week 48

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 48

  8. Percent Change From Baseline in Spine BMD at Week 96

    Spine BMD was assessed by DXA scan.

    Time frame: Baseline; Week 96

  9. Change From Baseline in Serum Creatinine at Week 48

    Time frame: Baseline; Week 48

  10. Change From Baseline in Serum Creatinine at Week 96

    Time frame: Baseline; Week 96

  11. Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

    Time frame: Baseline to Week 48

  12. Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

    Time frame: Baseline to Week 96

  13. Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

    Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 48

  14. Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

    Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 96

  15. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

    Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 48

  16. Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

    Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

    Time frame: Baseline; Week 96

07

Results

Posted Jan 8, 2016

Participant flow

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 12 March 2013. The last study visit occurred on 03 October 2018.

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneE/C/F/TAFE/C/F/TDF
Started435437
Completed348348
Not completed8789
Withdrew: Randomized but not treated42
Withdrew: Adverse event30
Withdrew: Death54
Withdrew: Pregnancy01
Withdrew: Lack of efficacy12
Withdrew: Investigator's discretion1517
Withdrew: Noncompliance with study drug51
Withdrew: Protocol violation01
Withdrew: Withdrew consent2035
Withdrew: Lost to follow-up3426
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneE/C/F/TAFE/C/F/TDF
Started141119
Completed140119
Not completed10
Withdrew: Investigator's discretion10

Outcome measures

PrimaryPercentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsE/C/F/TAFE/C/F/TDF
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 4891.688.5
Statistical analysis
  • E/C/F/TAF vs E/C/F/TDF · Cochran-Mantel-Haenszel · p = 0.13 · Difference in percentages: 3.1 · 95.002% CI -1.0 to 7.1The difference in percentages and its 95.002% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA and region stratum.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
percentage of participantsE/C/F/TAFE/C/F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 9684.082.3
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Weeks 48 and 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96
percentage of participantsE/C/F/TAFE/C/F/TDF
Week 4882.480.7
Week 9678.776.8
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLE/C/F/TAFE/C/F/TDF
Change From Baseline in CD4+ Cell Count at Week 48225 ± 171.2200 ± 162.5
SecondaryChange From Baseline in CD4+ Cell Count at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 96
cells/µLE/C/F/TAFE/C/F/TDF
Change From Baseline in CD4+ Cell Count at Week 96274 ± 184.0260 ± 179.6
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48-0.420 ± 3.2268-2.603 ± 3.1482
SecondaryPercent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Hip BMD at Week 96-0.364 ± 3.8990-3.023 ± 3.9796
SecondaryPercent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Spine BMD at Week 48-1.278 ± 3.0098-2.759 ± 3.0024
SecondaryPercent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan.

Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Spine BMD at Week 96-1.017 ± 3.3957-2.516 ± 3.8612
SecondaryChange From Baseline in Serum Creatinine at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 48
mg/dLE/C/F/TAFE/C/F/TDF
Change From Baseline in Serum Creatinine at Week 480.08 ± 0.1360.12 ± 0.283
SecondaryChange From Baseline in Serum Creatinine at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at Week 96
mg/dLE/C/F/TAFE/C/F/TDF
Change From Baseline in Serum Creatinine at Week 960.04 ± 0.1190.07 ± 0.122
SecondaryPercentage of Participants With Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

Time frame:
Baseline to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Proteinuria Through Week 48
percentage of participantsE/C/F/TAFE/C/F/TDF
Grade 127.331.6
Grade 24.74.6
Grade 300
SecondaryPercentage of Participants With Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.

Time frame:
Baseline to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Proteinuria Through Week 96
percentage of participantsE/C/F/TAFE/C/F/TDF
Grade 131.836.9
Grade 25.45.1
Grade 300
SecondaryPercent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 48
Reported as:
Median · percent change
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 4813.3 (-22.6 to 52.4)51.7 (2.6 to 138.6)
SecondaryPercent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 96
Reported as:
Median · percent change
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 9616.9 (-18.6 to 72.4)73.7 (10.4 to 196.3)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 48
Reported as:
Median · percent change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48-29.3 (-55.1 to 6.1)32.3 (-36.4 to 159.9)
SecondaryPercent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.

Time frame:
Baseline; Week 96
Reported as:
Median · percent change
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96
percent changeE/C/F/TAFE/C/F/TDF
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96-31.0 (-62.7 to 6.1)35.2 (-27.5 to 248.8)

Adverse events

Collected over First dose date to last dose date (maximum duration: 185 weeks during Double-Blind Phase and 102 weeks during Open-Label Extension Phase) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF (Double-Blind Phase)5/431 (1.2%)54/431 (12.5%)374/431 (86.8%)
E/C/F/TDF (Double-Blind Phase)4/435 (0.9%)68/435 (15.6%)366/435 (84.1%)
Open-Label E/C/F/TAF From E/C/F/TAF0/141 (0%)4/141 (2.8%)32/141 (22.7%)
Open-Label E/C/F/TAF From E/C/F/TDF0/119 (0%)2/119 (1.7%)27/119 (22.7%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventE/C/F/TAF (Double-Blind Phase)E/C/F/TDF (Double-Blind Phase)Open-Label E/C/F/TAF From E/C/F/TAFOpen-Label E/C/F/TAF From E/C/F/TDF
GastroenteritisInfections and infestations4/4310/4351/1410/119
AppendicitisInfections and infestations1/4314/4351/1410/119
Anal abscessInfections and infestations1/4310/4350/1411/119
Subcutaneous abscessInfections and infestations1/4311/4350/1411/119
Hiatus herniaGastrointestinal disorders0/4310/4351/1410/119
CholelithiasisHepatobiliary disorders2/4312/4351/1410/119
Hepatitis AInfections and infestations0/4310/4351/1410/119
AsthmaRespiratory, thoracic and mediastinal disorders3/4311/4350/1410/119
Pancreatitis acuteGastrointestinal disorders0/4313/4350/1410/119
Chest painGeneral disorders0/4313/4350/1410/119
Most frequent other events
Showing 10 of 39
Most frequent other events
EventE/C/F/TAF (Double-Blind Phase)E/C/F/TDF (Double-Blind Phase)Open-Label E/C/F/TAF From E/C/F/TAFOpen-Label E/C/F/TAF From E/C/F/TDF
DiarrhoeaGastrointestinal disorders99/431114/4350/1412/119
HeadacheNervous system disorders98/43180/4354/1412/119
Upper respiratory tract infectionInfections and infestations87/43182/4352/1412/119
NauseaGastrointestinal disorders78/43186/4351/1412/119
NasopharyngitisInfections and infestations68/43175/4355/1415/119
Back painMusculoskeletal and connective tissue disorders63/43153/4350/1410/119
CoughRespiratory, thoracic and mediastinal disorders62/43149/4351/1413/119
ArthralgiaMusculoskeletal and connective tissue disorders61/43149/4352/1410/119
FatigueGeneral disorders53/43152/4351/1410/119
InsomniaPsychiatric disorders51/43137/4351/1410/119

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)E/C/F/TAFE/C/F/TDFTotal
Mean35 ± 10.836 ± 10.936 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFE/C/F/TDFTotal
Female6271133
Male369364733
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFE/C/F/TDFTotal
American Indian or Alaska Native134
Asian151227
Black129132261
Native Hawaiian or Pacific Islander415
White235243478
Other474491
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFE/C/F/TDFTotal
Hispanic or Latino10797204
Not Hispanic or Latino323336659
Not Permitted112
Missing011
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAFE/C/F/TDFTotal
United States280282562
United Kingdom253156
Portugal211637
Canada192241
Netherlands6814
Sweden8311
Dominican Republic303565
Italy10818
Mexico161228
France161834
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)E/C/F/TAFE/C/F/TDFTotal
Mean4.53 ± 0.6474.50 ± 0.6904.52 ± 0.669
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAFE/C/F/TDFTotal
≤ 100,000 copies/mL339336675
> 100,000 to ≤ 400,000 copies/mL6882150
> 400,000 copies/mL241741
CD4 Cell Count
CD4 Cell Count(cells/µL)E/C/F/TAFE/C/F/TDFTotal
Mean414 ± 206.8431 ± 226.8423 ± 217.1

2 further baseline measures are reported on the registry.

08

Study locations

117 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Kaiser Permanente - Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • University of Southern California AIDS Clinical Trials Group
    Los Angeles, California 90033, United States
  • Peter J. Ruane, Inc.
    Los Angeles, California 90036, United States
  • Anthony Mills MD Inc
    Los Angeles, California 90069, United States
  • Alameda County Medical Center
    Oakland, California 94602, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • Kaiser Permanente San Francisco
    San Francisco, California 94118, United States
  • Kaiser Permanente
    San Leandro, California 94577, United States
  • Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center
    Torrance, California 90275, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • APEX Research LLC
    Denver, Colorado 80209, United States
  • Greenwich Hospital
    Greenwich, Connecticut 06830, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 20009, United States
  • Whitman-Walker Health
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34952, United States
  • AIDS Healthcare Foundation
    Miami Beach, Florida 33139, United States
  • AIDS Healthcare Foundation
    Miami, Florida 33133, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • Idocf/Valuhealthmd
    Orlando, Florida 32836, United States
  • Infectious Diseases Associates of NW FL
    Sarasota, Florida 32504, United States
  • University of South Florida
    Tampa, Florida 33602, United States
  • Infectious Disease Research Institute Inc.
    Tampa, Florida 33614, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida 33401, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Atlanta ID Group, PC
    Atlanta, Georgia 30309, United States
  • Emory University
    Atlanta, Georgia 30309, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialist of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University
    Macon, Georgia 31201, United States
  • University of Hawaii - Hawaii Center for AIDS
    Honolulu, Hawaii 96821, United States
  • Rush University Medical Center, Section of Infectious Diseases
    Chicago, Illinois 60305, United States
  • The Ruth M. Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02111, United States
  • The Research Institute
    West Springfield, Massachusetts 01105, United States
  • Be Well Medical Center
    Berkley, Michigan 48072-3436, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Central West Clinical Research
    Saint Louis, Missouri 63108, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • ID Care
    Hillsborough, New Jersey 08844, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Upstate ID Assoc
    Albany, New York 12208, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • North Shore University Hospital - Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • Chelsea Village Medical
    New York, New York 10011, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of North Carolina AIDS Clinical Trials Unit
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center Myer's Park Clinic
    Charlotte, North Carolina 28207, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • East Carolina University The Brody School of Medicine
    Greenville, North Carolina 27834, United States
  • Rosedale Infectious Disseases
    Huntersville, North Carolina 28078, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St. Hope Foundation, Inc.
    Bellaire, Texas 77401, United States
  • Trinity Health & Wellness Center / AIDS Arms, Inc.
    Dallas, Texas 75215, United States
  • Southwest Infectious Disease Clinical Research, Inc.
    Dallas, Texas 75219, United States
  • North Texas Infectious Diseases Consultants
    Dallas, Texas 75246, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot, MD, PA
    Houston, Texas 77098, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Clinical Alliance for Research & Education - Infectious Diseases (CARE-ID)
    Annandale, Virginia 22003, United States
  • Peter Shalit, MD
    Seattle, Washington 98104, United States
  • Research Institute of McGill University Health Care
    Montreal, Quebec H2X 2P4, Canada
  • Clinique Medicale L'actuel
    Montreal, H2L 4P9, Canada
  • University Health Network/Toronto General Hospital
    Toronto, M4N 3M5, Canada
  • Maple Leaf Research
    Toronto, M5G 1K2, Canada
  • Spectrum Health Care
    Vancouver, V6Z 2T1, Canada
  • Instituto Dominicano de Estudios Virologicos--IDEV
    Santo Domingo, 99999, Dominican Republic
  • Hopital de la Croix Rousse
    Lyon, 69004, France
  • University Hospital of Montpellier (CHU-Gui de Chauliac)
    Montpellier, 34295, France
  • Archet 1 CHU de Nice, Department of Infectiology
    Nice, 06200, France
  • Saint Louis Hospital of Infectious Diseases
    Paris, 75010, France
  • Hopital Saint Antoine
    Paris, 75012, France
  • Hôpital Bichat Claude Bernard
    Paris, 75018, France
  • Hopital Tenon
    Paris, 75020, France
  • Hopital Pitie Salpetriere
    Paris, 75651, France
  • CH Tourcoing
    Tourcoing, 59208, France
  • Universitaria di Bologna-Policlicnico S' Orsola Malpighi
    Bologna, 40138, Italy
  • IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
  • Hospital Civil de Guadalajara
    Guadalajara, 44280, Mexico
  • Insituto Nacional De Enfermedades Respiratorias "Ismael Cosio Villegas"
    Mexico City, 14080, Mexico
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, 1091 AC, Netherlands
  • Serviço de Doenças Infecciosas, HUC-CHUC, EPE
    Coimbra, 3000-075, Portugal

Showing the first 100 of 117 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum In: Lancet. 2016 Apr 30;387(10030):1816. doi: 10.1016/S0140-6736(16)30252-5. PubMed 25890673 ↗
  • Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks. J Clin Virol. 2018 Jun;103:37-42. doi: 10.1016/j.jcv.2018.03.012. Epub 2018 Apr 2. PubMed 29627709 ↗
  • Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350. PubMed 28282300 ↗
  • Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11. PubMed 28076335 ↗
  • Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731. PubMed 26892863 ↗
  • Funderburg NT, McComsey GA, Kulkarni M, Bannerman T, Mantini J, Thornton B, Liu HC, Zhang Y, Song Q, Fang L, Dinoso J, Cheng A, McCallister S, Fordyce MW, Das M. Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 2016 Nov;13:321-327. doi: 10.1016/j.ebiom.2016.10.009. Epub 2016 Oct 11. PubMed 27742226 ↗
  • Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-2,92-01040111 and Study Team. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940. PubMed 26829661 ↗
  • Custodio JM, Garner W, Callebaut C, Fordyce M, Plummer A, Zhong L, et al. The Pharmacokinetics of Tenofovir and Tenofovir Diphosphate Following Administration of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate [Oral Abstract #6]. The 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington DC, USA, May 26-28, 2015.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Sep 2014, 18 months.

Results were first posted in Jan 2016, 1 year 3 months after primary completion. A results delay was requested in Jul 2015.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 18 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2013
First posted
Feb 22, 2013
StartActual
Mar 12, 2013
Primary completionActual
Sep 19, 2014
CompletionActual
Oct 3, 2018
Results delay requested
Jul 28, 2015
Results first posted
Jan 8, 2016
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01797445
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 22, 2013
Start date
Mar 12, 2013
Primary completion
Sep 19, 2014
Completion
Oct 3, 2018
Results posted
Jan 8, 2016
Last update
Mar 2, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion